AI-generated research brief — verify at source
One in Three Chemotherapy Patients Presents Unplanned, Most Often in Cycle One
Among 346 adult oncology patients followed through their first three chemotherapy cycles, one-third (33%) made at least one unplanned hospital presentation, with 51% of all such presentations occurring during cycle one alone. Lung cancer and stage IV disease independently predicted higher presentation rates, while over half of all unplanned visits did not lead to hospital admission, signaling a potential gap in community-based symptom management.
What Was Studied
This study investigated how frequently oncology patients receiving chemotherapy make unplanned hospital visits, what symptoms drive those visits, and which patient characteristics place individuals at higher risk. Understanding these patterns is important for identifying where supportive care interventions are most needed and whether emergency department use could be reduced through earlier or alternative care pathways.
How It Was Studied
This was a pre-specified secondary analysis drawing on data from a randomized controlled trial conducted across two tertiary hospitals in Australia. The dataset covered adult oncology patients receiving chemotherapy, with hospital utilization recorded across the first three treatment cycles. Descriptive statistics were applied to characterize the pattern and timing of unplanned presentations, while Poisson regression modeling was used to identify independent risk factors associated with presentation rates. The sample included 346 patients, providing a reasonably sized cohort for exploring clinical predictors within a controlled trial framework.
What Was Observed
- Unplanned presentations were common and heavily front-loaded: 115 of 346 patients (33%) had one or more unplanned hospital visits across the first three chemotherapy cycles, and 74 of 144 total presentations (51%) occurred during cycle one, suggesting that the period immediately following treatment initiation carries the greatest burden of acute side effects requiring urgent attention.
- Fever and nausea were the dominant presenting complaints: Fever with or without neutropenia accounted for 35% of presentations (n = 50), while nausea and vomiting represented 21% (n = 30). These two symptom categories together drove more than half of all unplanned visits, identifying them as primary targets for improved prophylactic and supportive care strategies.
- Most unplanned presentations did not lead to admission: 52% of all unplanned presentations (n = 75) resolved without inpatient admission, suggesting that many visits may represent urgent but not life-threatening symptom crises. Among those admitted, 70 patients (20% of the overall cohort) had a median hospital stay of 3 days (IQR 2–7).
- Cancer stage and type were independent predictors of unplanned presentations: Patients with stage IV disease had approximately 2.5 times the presentation rate of those with stage I disease (IRR 2.50, 95% CI 1.28–4.89; P = 0.01), a statistically meaningful difference indicating that disease burden substantially influences care demands. Patients with lung cancer had approximately 2.25 times the rate seen in breast cancer patients (IRR 2.25, 95% CI 1.26–4.01; P = 0.01), reflecting likely differences in treatment toxicity and patient baseline status.
Why This Matters
These findings contribute quantitative detail to a recognized but incompletely mapped problem in oncology: unplanned acute care utilization during chemotherapy. The concentration of presentations in cycle one points to an actionable window for enhanced monitoring and patient education before and immediately after treatment initiation. The high proportion of presentations that did not result in admission raises a question central to health system design — whether primary care or structured outpatient services could intercept a meaningful share of these visits before they reach the emergency department.
How to Read This Result
Because this is a secondary analysis of a trial conducted at two Australian tertiary centers, the findings may not fully generalize to community oncology settings or healthcare systems with different supportive care infrastructures, and the original trial’s design and eligibility criteria may have introduced selection effects that limit the representativeness of the presentation rates reported.
Limitations
The abstract does not explicitly report study limitations.